# Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

> **NCT07676331** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 168 (estimated)

## Conditions studied

- Hormone-receptor-positive Breast Cancer
- Early Breast Cancer

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Letrozole (Aromatase Inhibitors)

## Key facts

- **NCT ID:** NCT07676331
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07676331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07676331, "Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07676331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*